ISOFOL MEDICAL AB December 2021
Setting the stage for arfolitixorin's market launch
-planned for 2023
© ISOFOL MEDICAL AB (publ)
Disclaimer
This company presentation of Isofol Medical AB (publ) ("Isofol") has been prepared for advertisement purposes. It is not a prospectus and has not been prepared in accordance with the prospectus requirements in the Swedish Financial Instruments Trading Act (lagen (1991:980) om handel med finansiella instrument) or the European prospectus regulation (809/2004/EC) (the "Prospectus Regulations"). This company presentation is not subject to any registration or approval requirements under the Prospectus Regulations and has not been, and will not be, examined, approved or registered by the Swedish Financial Supervisory Authority or any financial supervisory authority or other supervisory body within the EU.
The company presentation may not be forwarded, reproduced or made available in or into any jurisdiction in which such publication or distribution would require any additional documentation to be prepared or registration effected or that any measures are taken in addition to those required under Swedish law or where it would be in conflict with any law or regulation in such jurisdiction. Persons who come into possession of this document are required to inform themselves about, and to observe, such restrictions.
The courts of Sweden shall have exclusive jurisdiction over any dispute arising out of or in connection with this document company presentation and the City Court of Gothenburg, Sweden, shall be the court of first instance.
© ISOFOL MEDICAL AB (publ) | 2 |
Isofol at a glance
Isofol was founded in 2008 in Gothenburg, secured funding of an additional MSEK 452 in June 2021 and listed on Nasdaq Stockholm in October 2021
Isofol develops arfolitixorin for the treatment of colorectal cancer (CRC), the third most common cancer type
Since 2013 Isofol have strategic CMC partnerships with Merck & Cie and Recipharm
Isofol has two strategic licensing agreements from 2020 with Solasia Pharma KK in Japan and Endo/Paladin in Canada
Late stage fully recruited phase III study with Top-Line results estimated during H1 2022
Pre-commercialization activities initiated, including the development of medical affairs and commercial launch packages
Shareholders | Number of | Capital/Votes |
shares | (%) | |
Futur Pension | 13,335,256 | 8.26% |
Avanza Pension | 7,927,068 | 4.91% |
Handelsbanken Fonder | 5,938,471 | 3.68% |
Nordnet Pensionsförsäkring | 5,433,172 | 3.36% |
Swedbank Försäkring | 5,268,567 | 3.26% |
Hans Enocson | 4,555,236 | 2.82% |
Fjärde AP-fonden | 4,521,257 | 2.80% |
Swedbank Robur Fonder | 4,175,839 | 2.59% |
Bengt Gustafsson* | 3,749,459 | 2.32% |
Peak Asset Management | 3,381,964 | 2.09% |
10 larges share owners | 58,286,289 | 36.09% |
Other owners | 103,229,111 | 63.91% |
TOTAL | 161,151,440 | 100% |
Number of shareholders approx. 4500
Source: The list of Isofol´s largest shareholders is based on information from Euroclear Sweden AB as of 30 September 2021. * Own or related natural or legal person holding shares (direct and indirect) and other financial instruments in the company
© ISOFOL MEDICAL AB (publ) | 3 |
Colorectal cancer (CRC) - Large and underserved segment
3rd most common and 2nd deadliest cancer with an urgent large unmet need
COLORECTAL CANCER FACTSHEET
Colorectal cancer is the third most common cancer1
10% of cancers discovered annually are colorectal cancer
(millions) | 2,4 | 12% | 11% | |||
10% | ||||||
2,2 | ||||||
2,0 | ||||||
incidence | 1,8 | 7% | ||||
1,6 | 5% | |||||
1,2 | ||||||
1,4 | 6% | |||||
global | 1,0 | |||||
0,8 | ||||||
Annual | 0,6 | |||||
0,4 | ||||||
0,2 | ||||||
0,0 | ||||||
Lung | Breast Colorectal Prostate Stomach | Liver | ||||
1.9M 1.9M people are diagnosed with CRC each year globally1
10 The 5-year survival rate for patients % with stage 4 colorectal cancer (mCRC)
falls to around 10%2
GROWING INCIDENCE
>60% The global burden of CRC is expected to increase by over 60% from 1.9M 2020 cases to 3.1M in 20401
GLOBAL CRC MARKET $10.6B IN 2028
Total market size will grow ~$3B from 2018 to 20282
10.6
7.5
2028
2018
© ISOFOL MEDICAL AB (publ) | Source: 1) | GLOBOCAN 2020, Cancer Incidence and Mortality Worldwide | 4 |
2) | GlobalData 2020 | ||
Strategic priorities - Paving the way for success
Strategic priorities
1 Finalizing the global phase III AGENT study
2 Continue to execute on strategic partnerships in Japan and Canada
3 Evaluate partnering options
4 Build arfolitixorin awareness and value through accelerated pre-commercialization activities
© ISOFOL MEDICAL AB (publ) | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Isofol Medical AB published this content on 08 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 December 2021 14:51:02 UTC.
